BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668 [PMID: 31391764 DOI: 10.3748/wjg.v25.i28.3664]
URL: https://www.wjgnet.com/2150-5330/full/v25/i28/3664.htm
Number Citing Articles
1
Kavita Garg, Trenton Reinicke, Satish K. Garg. NAFLD and NASH and DiabetesDiabetes Technology & Therapeutics 2021; 23(S2): S-198 doi: 10.1089/dia.2021.2515
2
Mario Simental-Mendía, Adriana Sánchez-García, Mariana Rodríguez-Ramírez, Luis E. Simental-Mendía. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trialsPharmacological Research 2021; 163: 105319 doi: 10.1016/j.phrs.2020.105319
3
Virginia Bellido, Julia Martínez, Fernando Calvo, Aida Villarroel, Edurne Lecumberri, Juan Moreno, Carlos Morillas, Silvia Rodrigo, Aitziber Izarra, Albert Lecube. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical ComplicationsDiabetes Therapy 2022; 13(5): 873 doi: 10.1007/s13300-022-01237-9
4
Tiantian Song, Shuchun Chen, Hang Zhao, Fei Wang, Huan Song, Dongliang Tian, Qiwen Yang, Licui Qi. Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver diseaseHepatology Research 2021; 51(6): 641 doi: 10.1111/hepr.13645
5
Meng Yang, Chang-An Geng, Xinguang Liu, Min Guan. Lipid Disorders in NAFLD and Chronic Kidney DiseaseBiomedicines 2021; 9(10): 1405 doi: 10.3390/biomedicines9101405
6
Junwei Shao, Tiantian Ge, Yingliang Wei, Yuhan Zhou, Mengyuan Shi, Huiyuan Liu, Zhi Chen, Yang Xia. Co-interventions withClostridium butyricumand soluble dietary fiber targeting the gut microbiota improve MAFLDviathe Acly/Nrf2/NF-κB signaling pathwayFood & Function 2022; 13(10): 5807 doi: 10.1039/D1FO04224F